Compare Abeona Therapeutics Inc (ABEO) vs Wayfair Inc (W) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Wayfair Inc — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Wayfair Inc trades at $86.08 (market cap $12.31B). The key difference: Wayfair Inc is far larger — about 33× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Wayfair Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | W | |
|---|---|---|
Market Cap | $373.32M | $12.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $119.05 |
52-Week Low | $4.17 | $53.37 |
Enterprise Value | $228.22M | $14.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Wayfair (W) trades at $93.18, down 1.4% today, with a bullish technical outlook supported by moving averages and positive momentum indicators. The company shows mixed fundamentals with strong revenue growth to $12.46B in 2025 but negative net income margins of -2.41%. Recent analyst upgrades to Strong Buy highlight optimism around earnings potential, though high debt levels and competitive pressures remain concerns.
Investment outlook balances strong analyst support (52% buy ratings) against fundamental challenges including negative profitability and elevated debt. The stock offers momentum potential with upcoming Q2 earnings on August 4, 2026 as a key catalyst, but requires careful monitoring of margin improvement and debt management for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
